Treatment options for multiple myeloma have increased substantially, mainly attributed to advancements in clinical trials. More than ever, HCPs having conversations about trials is critical. Given that underrepresented communities bear a disproportionate burden of multiple myeloma, it becomes imperative to shift this paradigm. What are the optimal approaches to initiate these conversations early in the patient journey? How should HCPs effectively communicate information about clinical trials to patients and their families, including care partners? Renowned experts Dr. Craig Cole and Charise Gleason lend their expertise, offering insights into best practices and guidance on the next steps to be taken.
- How to explain the sequence of myeloma treatment and how available clinical trials fit
- HCP-to-HCP recommended strategies for initiating clinical trial conversations early in the myeloma patient journey
- How to effectively mitigate and manage concerns regarding clinical trials, through education, and continuously encourage patients and care partners to ask questions.
Register to watch online on Tuesday, March 5th @ 10 AM Pacific | 1 PM Eastern. This roundtable is moderated by a fellow HCP.
The webinar will be recorded. If you would like to share it with others, the replay will be available within the next few days. To receive a link to the recording, please register and you will be notified when it’s available.I'll be at the March 5th HCP Roundtable: Critical Clinical Trial Conversations in the Expanding Myeloma Landscape webinar. Join me! Click To Tweet
Advocacy Promotional Partners
This program is brought to you by the Patient Empowerment Network. It is made possible through support from Bristol Myers Squibb and generous donations from people like you.